Parabilis Medicines closed a $305 million Series F to advance zolucatetide (FOG‑001) toward Phase III for desmoid tumors; the company said the financing sparked IPO speculation. Parabilis emphasized its Helicon platform to target intracellular, historically 'undruggable' biology and noted FDA Fast Track status for FOG‑001. In parallel, Arkin Capital closed a $100 million Arkin Bio Ventures III fund to back 10–12 early‑stage biotech companies with a focus on oncology, immunology, inflammation and rare disease. Arkin said the fund will target late preclinical and early clinical programs expected to reach proof‑of‑concept with the new capital. These financings point to renewed investor willingness to back clinical inflection‑point programs and earlier stage platform plays after a cautious market cycle, especially in modalities addressing unmet needs.